Drug Profile
Anti D Rho immunoglobulin - Kamada
Alternative Names: Anti-D immunoglobulin; WinRho SDFLatest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Developer Baxter Healthcare Corporation; Emergent BioSolutions; Kamada
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunoglobulin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura
- No development reported Dengue; Thrombocytopenia
Most Recent Events
- 31 Dec 2022 Launched for Haemolytic disease of newborn in Kuwait, Uruguay, Saudi Arabia, South Korea, United Arab Emirates (IV) as of December 2022
- 31 Dec 2022 Launched for Idiopathic thrombocytopenic purpura in South Korea, United Arab Emirates, Uruguay, Kuwait, Saudi Arabia (IV) as of December 2022
- 31 Dec 2022 Registered for Haemolytic disease of newborn in Kuwait, Saudi Arabia, South Korea, United Arab Emirates, Uruguay, Iraq (IV) as of December 2022